Group 1 - The core viewpoint of the report is that Huatai Medical (688617.SH) is rated as a "buy" due to its rapid expansion following the launch of new PFA products and the completion of a comprehensive product layout [2] - The report highlights impressive growth in coronary and peripheral interventions, with an increasing number of hospital admissions [2] Group 2 - The report mentions potential risks including the impact of medical insurance cost control policies, delays in the progress of research projects, and challenges in product promotion [2]